MedTrace Logo

ADYNOVATE Drug Use-Results Survey

NCT03169972 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 135

Last updated 2025-02-04

Study results available
· View outcomes & findings →

Summary

The purpose of this survey is to understand the following items in the actual clinical use of ADYNOVATE in patients:

1. Unexpected adverse drug reactions
2. Occurrence of adverse drug reactions in the actual clinical use
3. Factors that may affect safety and efficacy
4. Occurrence of Factor VIII inhibitor development in patients with coagulation factor VIII deficiency (hereinafter hemophilia A)
5. Safety and efficacy for hemophilia A patients who received routine prophylactic therapy and on-demand therapy

Conditions

Interventions

BIOLOGICAL

ADYNOVATE

Antihemophilic Factor (Recombinant), PEGylated

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-01
Primary Completion
2023-09-15
Completion
2023-09-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03169972 on ClinicalTrials.gov